Ensign Peak Advisors, Inc Acadia Pharmaceuticals Inc Transaction History

Ensign Peak Advisors, Inc

$54.2 Billion
Q1 2024

A detailed history of Ensign Peak Advisors, Inc transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 60,450 shares of ACAD stock, worth $982,312. This represents 0.0% of its overall portfolio holdings.

Number of Shares

60,450

Previous 63,500 4.8%

Holding current value

$982,312

Previous $1.99 Million 43.81%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$17.79 - $30.86 $54,259 - $94,123	-3,050 Reduced 4.8%	60,450 $1.12 Million
Q4 2022 Feb 13, 2023	BUY	$14.2 - $18.63 $333,700 - $437,805	23,500 Added 58.75%	63,500 $1.01 Million
Q3 2022 Nov 14, 2022	SELL	$14.11 - $18.27 $1.43 Million - $1.85 Million	-101,470 Reduced 71.73%	40,000 $654,000
Q2 2022 Aug 12, 2022	BUY	$13.01 - $27.22 $1.32 Million - $2.76 Million	101,470 Added 253.68%	141,470 $1.99 Million
Q1 2022 May 16, 2022	BUY	$20.94 - $27.5 $214,006 - $281,050	10,220 Added 34.32%	40,000 $969,000

Q4 2021 Feb 11, 2022	BUY	$16.79 - $27.09 $500,006 - $806,740	29,780 New	29,780 $695,000
Q2 2021 Aug 13, 2021	SELL	$19.4 - $27.42 $1.16 Million - $1.64 Million	-59,702 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$25.02 - $54.99 $1.53 Million - $3.36 Million	-61,137 Reduced 50.59%	59,702 $1.54 Million
Q4 2020 Feb 12, 2021	SELL	$41.04 - $56.79 $223,216 - $308,880	-5,439 Reduced 4.31%	120,839 $6.46 Million
Q3 2020 Nov 12, 2020	BUY	$36.42 - $57.0 $3.99 Million - $6.24 Million	109,515 Added 653.31%	126,278 $5.21 Million
Q2 2020 Aug 12, 2020	BUY	$39.26 - $52.73 $96,972 - $130,243	2,470 Added 17.28%	16,763 $813,000
Q1 2020 May 11, 2020	BUY	$31.65 - $46.87 $452,373 - $669,912	14,293 New	14,293 $604,000

Others Institutions Holding ACAD

# of Institutions

299

Shares Held

158M

Call Options Held

1.88M

Put Options Held

688K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.63B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.

Account

Ensign Peak Advisors, Inc Acadia Pharmaceuticals Inc Transaction History